Botulinum Toxin A Injections to the Upper Limbs in Children With Cerebral Palsy: Duration of Effect

Abstract

We report our experience on the duration of effectiveness of botulinum toxin A injections to the upper extremities of children with cerebral palsy. A retrospective chart review was conducted on 30 consecutive patients (mean age, 9.9 ± 5.0 years) with spastic hemiparesis and quadriparesis. They received 1 to 5 treatments, totaling 56 treatments for the entire cohort. The injected muscles were the pronator teres (50/56), flexor carpi radialis (39/56), biceps (38/56), flexor carpi ulnaris (35/56), opponens (21/56), and adductor pollicis (17/56). Children were assessed for muscle tone and classified according to the Manual Ability Classification System before and after treatment. Functional improvement was apparent after 42 of 56 treatments, and muscle tone decreased significantly (P < .001). The mean duration of the effect was 7.0 ± 3.0 months. We conclude that the effect of botulinum toxin A to the upper limbs is retained for longer periods of time than those reported for lower limbs.

Keywords

botulinum toxin type A upper limbs duration of effect

Get full access to this article

View all access options for this article.

References

Wasiak J. , Hoare B. , Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev. 2004; CD003469.

Wall SA , Chait LA , Temlett JA , et al. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg. 1993;46:703-706.

Mall V. , Heinen F. , Linder M. , et al. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil. 1997;1:235-237.

Boyd RN , Morris ME , Graham HK Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol. 2001;(Suppl5):150-166.

Hoare B. , Imms C. Upper-limb injections of botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. Am J Occup Ther. 2004;58:389-397.

Sakzewski L. , Ziviani J. , Boyd R. Systematic review and meta-analysis of therapeutic management of upper-limb dysfunction in children with congenital hemiplegia. Pediatrics. 2009;123: e1111-e1122.

Corry IS , Cosgrove AP , Walsh EG , et al. Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol. 1997;39:185-193.

Fehlings D. , Rang M. , Glazier J. , Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr. 2000;137: 331-337.

Speth LA , Leffers P. , Janssen-Potten YJ , Vles JS Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol. 2005;47:468-473.

10.

Reeuwijk A. , Van Schie PE , Becher JG , Kwakkel G. Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review. Clin Rehabil. 2006;20: 375-387.

11.

Wallen M. , O’Flaherty SJ , Waugh MC Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil. 2007;88:1-10.

12.

Brin MF Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-S168.

13.

Heinen F. , Desloovere K. , Schroeder S. , et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Pediatr Neurol . 2010;14: 45-66.

14.

Palisano JR , Cameron D. , Rosenbaum PL , et al. Stability of the Gross Motor Function Classification System. Dev Med Child Neurol. 2006;48:424-428.

15.

Eliasson AC , Krumlinde-Sundholm L. , Rösblad B. , et al. The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol. 2006;48:549-554.

16.

Boyd RN , Graham HK Botulinum toxin A in the management of children with cerebral palsy-indications and outcome. Eur J Neurol. 1997;(Suppl):15-22.

17.

Boyd RN , Graham HK Objective clinical measures in the use of Botulinum toxin A in the management of cerebral palsy. Eur J Neurol. 1999;(Suppl4):23-36.

18.

Allergan Inc. BOTOX(R) (OnabotulinumtoxinA) receives FDA approval for treatment of upper limb spasticity in adults. Published: March 9th, 2010; agn.client.shareholder.com.

19.

Sätilä H. , Kotamäki A. , Koivikko M. , Autti-Rämö I. Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases. Pediatr Rehabil. 2006;9:247-258.

20.

Autti-Rämö I. , Larsen A. , Taimo A. , et al. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol. 2001;8:136-144.

21.

Wissel J. , Heinen F. , Schenkel A. , et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of ‘‘high-dose’’ versus ‘‘low-dose’’ treatment. Neuropediatrics. 1999;30:120-124.

22.

Herrman J. , Geth K. , Mall V. , et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004;55: 732-735.

23.

Fattal-Valevski A. , Domenievitz D. , Giladi N. , et al. Long-term effect of repeated injections of botulinum toxin in children with cerebral palsy-a prospective study. J Child Orthop. 2008;2:29-35.